You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

 

4885 Results
Regimen
Cancer Type:
Gynecologic, 
Ovary
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
    letrozole
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
letrozole
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Nov 2020
Regimen
Cancer Type:
Genitourinary, 
Testis
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
gemcitabine,
oxaliplatin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2019
Regimen
Cancer Type:
Skin, 
Melanoma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
CARBOplatin,
PACLitaxel
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Oct 2017
Regimen
Cancer Type:
Skin, 
Squamous Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
cetuximab (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jul 2023
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Hodgkin
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Drugs Used:
vinCRIStine,
procarbazine,
prednisone,
DOXOrubicin,
cyclophosphamide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2019
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Hodgkin
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Drugs Used:
vinCRIStine,
etoposide,
prednisone,
DOXOrubicin,
cyclophosphamide,
dacarbazine
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2020
Regimen
Cancer Type:
Hematologic, 
Myeloproliferative Neoplasms (MPNs)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
pegylated interferon alpha 2a (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2019
Regimen
Cancer Type:
Hematologic, 
Lymphoma - T-cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative, Palliative
Drugs Used:
CISplatin,
etoposide,
ifosfamide,
mesna,
dexamethasone
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2019
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
    melphalan - oral tablets
ODB - General Benefit
    dexamethasone
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
melphalan,
dexamethasone
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2019
Regimen
Cancer Type:
Skin, 
Melanoma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    daBRAfenib - In combination with trametinib for the treatment of BRAF V600 mutation-positive, unresectable or metastatic melanoma, according to specific clinical criteria
Exceptional Access Program
    trametinib - In combination with dabrafenib for the treatment of BRAF V600 mutation-positive, unresectable or metastatic melanoma, according to specific clinical criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
daBRAFenib,
trametinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2021
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
ramucirumab (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2023
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    idelalisib - For the treatment of relapsed chronic lymphocytic leukemia, in combination with rituximab, according to specific clinical criteria
New Drug Funding Program
    Rituximab (Biosimilar IV) - In Combination with Idelalisib - Relapsed Chronic Lymphocytic Leukemia
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
idelalisib,
riTUXimab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Nov 2023

Pages